Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -56.07% | 2.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -56.07% | 2.37% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -56.07% | 2.37% | |||
| SG&A Expenses | 22.20% | -12.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.92% | -29.05% | |||
| Operating Income | 17.42% | 29.34% | |||
| Income Before Tax | 33.94% | -264.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.94% | -264.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.94% | -264.37% | |||
| EBIT | 17.42% | 29.34% | |||
| EBITDA | 17.58% | 29.68% | |||
| EPS Basic | 37.20% | -267.20% | |||
| Normalized Basic EPS | 33.58% | -235.49% | |||
| EPS Diluted | 36.85% | -269.49% | |||
| Normalized Diluted EPS | 33.58% | -236.09% | |||
| Average Basic Shares Outstanding | 0.05% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.05% | -0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||